NEWS
Ten Years of Tamoxifen Leads to Fewer Breast Cancer Recurrences, Improves Survival SABCS
For some women with breast cancer, taking tamoxifen for 10 years after primary treatment (adjuvant therapy) leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.
The findings from the ATLAS trial—presented at the San Antonio Breast Cancer Symposium (SABCS) and published in The Lancet on December 5—are likely to change clinical practice, several researchers said. Read more >>
Chemotherapy after Surgery Improves Survival When Some Breast Cancers Return SABCS
New regimen especially effective for women with estrogen receptor-negative tumorsNew Targeted Treatment May Slow Disease in Patients with Advanced GIST
Regorafenib is effective against tumors that are resistant to other treatmentsStudy Explores Why Double Mastectomy Rate Is on the Rise ASCO
Concern about recurrence played significant role in women's decisionsHigher Dose of Breast Cancer Drug Associated with Longer Survival SABCS
Study confirms benefit of higher dose of fulvestrant for advanced breast cancerNoninvasive Test for Kidney Cancer May Lessen Need for Surgery
124I-girentuximab PET/CT can accurately detect clear cell renal cell carcinomas
A MESSAGE TO READERS
NCI Cancer Bulletin Publication Break
The NCI Cancer Bulletin will not be published on December 25. Our next issue will be published on January 8, when we resume our usual biweekly publication schedule.
To find stories from past issues, please visit our archive/search page.To suggest a cancer research topic that you would like to see covered in the coming year, send us your feedback here.
IN DEPTH
Experimental Drug Shows Promise against Drug-Resistant Leukemias ASH
Ponatinib is active against all known mutations in the BCR-ABL protein
Comparative Oncology: Man's Best Friend in More Ways than One
Through NCI's Comparative Oncology Program, researchers are studying cancers in dogs to help inform human clinical trials
Featured Clinical Trial: Treating Patients with High-Risk Smoldering Myeloma
Will early treatment of asymptomatic multiple myeloma delay the onset of symptoms?
Profiles in Cancer Research: Dr. Titia de Lange
The NCI-funded researcher studies the molecular and cell biology of telomeres and how telomere function is altered in cancer
UPDATES
FDA Update
- Abiraterone Approval Extended to Treat Late-Stage Prostate Cancer
- Cabozantinib Approved to Treat Rare Type of Thyroid Cancer
Notes
- New National Cancer Advisory Board Members Named
- NCI Recognizes 12 Clinical Investigators with Leadership Awards
- National Cancer Advisory Board Discusses NCI Funding Patterns, Program Updates
- NCI FY2013 Budget Proposal Published Online
- NCI E-Books Available on Mobile Website
- Annual Report on NCI Disparities Research Released
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
